Literature DB >> 3627174

The natural history of lone atrial fibrillation. A population-based study over three decades.

S L Kopecky, B J Gersh, M D McGoon, J P Whisnant, D R Holmes, D M Ilstrup, R L Frye.   

Abstract

From 1950 to 1980, 3623 patients from Olmsted County, Minnesota, were found to have atrial fibrillation. Ninety-seven of these patients (2.7 percent), who were 60 years old or younger at diagnosis, had lone atrial fibrillation (atrial fibrillation in the absence of overt cardiovascular disease or precipitating illness), and their data were reviewed to determine the incidence of thromboemboli. Twenty of these patients (21 percent) had an isolated episode of atrial fibrillation, 56 (58 percent) had recurrent atrial fibrillation, and 21 (22 percent) had chronic atrial fibrillation. The total follow-up period was 1440 person-years, with a mean of 14.8 years per patient. The mean age at diagnosis was 44 years. Nineteen cardiovascular events occurred in 17 patients; 4 patients had strokes thought to be due to emboli from atrial fibrillation, and 4 had myocardial infarctions without overt evidence of previous coronary artery disease. The probability of survival at 15 years was 94 percent among the patients with lone atrial fibrillation. At 15 years, 1.3 percent of the patients had had a stroke on a cumulative actuarial basis. On an actuarial basis, there was no difference in survival or in survival free of stroke among the patients with the three types of lone atrial fibrillation (i.e., isolated, recurrent, and chronic). We conclude that lone atrial fibrillation in patients under the age of 60 at diagnosis is associated with a very low risk of stroke. This suggests that routine anticoagulation may not be warranted.

Entities:  

Mesh:

Year:  1987        PMID: 3627174     DOI: 10.1056/NEJM198709103171104

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  140 in total

1.  Effects of pretreatment with verapamil on early recurrences after electrical cardioversion of persistent atrial fibrillation: a randomised study.

Authors:  E Bertaglia; D D'Este; A Zanocco; F Zerbo; P Pascotto
Journal:  Heart       Date:  2001-05       Impact factor: 5.994

2.  Acute pressure overload cardiac arrhythmias are dependent on the presence of myocardial tissue catecholamines.

Authors:  A J Drake-Holland; M I Noble; M J Lab
Journal:  Heart       Date:  2001-05       Impact factor: 5.994

Review 3.  When atrial fibrillation occurs with pulmonary embolism, is it the chicken or the egg?

Authors:  K M Flegel
Journal:  CMAJ       Date:  1999-04-20       Impact factor: 8.262

Review 4.  Idiopathic atrial fibrillation: prevalence, course, treatment, and prognosis.

Authors:  S L Kopecky
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 5.  Chronic and paroxysmal atrial fibrillation: course, prognosis, and stroke risk.

Authors:  T E Cuddy
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 6.  Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management.

Authors:  I Savelieva; A J Camm
Journal:  J Interv Card Electrophysiol       Date:  2000-06       Impact factor: 1.900

7.  Evaluation of quantification methods for left arial late gadolinium enhancement based on different references in patients with atrial fibrillation.

Authors:  Sung Ho Hwang; Yu-Whan Oh; Dae In Lee; Jaemin Shim; Sang-Weon Park; Young-Hoon Kim
Journal:  Int J Cardiovasc Imaging       Date:  2014-11-04       Impact factor: 2.357

Review 8.  Mechanisms underlying the development of atrial arrhythmias in heart failure.

Authors:  Vias Markides; Nicholas S Peters
Journal:  Heart Fail Rev       Date:  2002-07       Impact factor: 4.214

Review 9.  Ablation of atrial fibrillation.

Authors:  Eduardo B Saad; Nassir F Marrouche; Andrea Natale
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

Review 10.  Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.

Authors:  Gerald V Naccarelli; John Hynes; Deborah L Wolbrette; Luna Bhatta; Mazhar Khan; Jerry Luck
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.